Anti-inflammatory properties of the μ opioid receptor support its use in the treatment of colon inflammation

• Published in: The Journal of clinical investigation 2003-05, Vol.111 (9), p.1329-1338
• Main Authors: Philippe, David, Dubuquoy, Laurent, Groux, Hervé, Brun, Valérie, Chuoï-Mariot, Myriam Tran Van, Gaveriaux-Ruff, Claire, Colombel, Jean-Frédéric, Kieffer, Brigitte L., Desreumaux, Pierre
• Format: Article
• Language: English
• ISSN: 0021-9738
• DOI: 10.1172/JCI200316750

The physiologic role of the μ opioid receptor (MOR) in gut nociception, motility, and secretion is well established. To evaluate whether MOR may also be involved in controlling gut inflammation, we first showed that subcutaneous administration of selective peripheral MOR agonists, named DALDA and DAMGO, significantly reduces inflammation in two experimental models of colitis induced by administration of 2,4,6-trinitrobenzene sulfonic acid (TNBS) or peripheral expansion of CD4 + T cells in mice. This therapeutic effect was almost completely abolished by concomitant administration of the opioid antagonist naloxone. Evidence of a genetic role for MOR in the control of gut inflammation was provided by showing that MOR-deficient mice were highly susceptible to colon inflammation, with a 50% mortality rate occurring 3 days after TNBS administration. The mechanistic basis of these observations suggests that the anti-inflammatory effects of MOR in the colon are mediated through the regulation of cytokine production and T cell proliferation, two important immunologic events required for the development of colon inflammation in mice and patients with inflammatory bowel disease (IBD). These data provide evidence that MOR plays a role in the control of gut inflammation and suggest that MOR agonists might be new therapeutic molecules in IBD.